📰
Politics
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
📅24 February 2026 at 09:00
📰NaijNaira
👁️0 views
Share:
📰
Article Preview
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed…
The post Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China appeared first on NaijNaira.
🎧
Listen to Preview
Audio version available
🔇
Audio Reader
Not supported in this browser
Want the full story?
Click below to load the complete article with full details, analysis, and context.
Share this story
Share:
Source: This article was originally published by NaijNaira. All rights reserved to the original publisher.
Comments
Loading comments...
Related Stories
Stay Updated
Get the latest Nigerian news delivered to your inbox.